PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
Wolters Kluwer Health
2022
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/23831/1/23831.pdf |
| _version_ | 1824417026265841664 |
|---|---|
| author | Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, Hagop M. Gómez Almaguer, David Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J. M. |
| author_facet | Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, Hagop M. Gómez Almaguer, David Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J. M. |
| author_sort | Jabbour, E. |
| collection | Repositorio Institucional |
| format | Article |
| id | eprints-23831 |
| institution | UANL |
| language | English |
| publishDate | 2022 |
| publisher | Wolters Kluwer Health |
| record_format | eprints |
| spelling | eprints-238312024-03-05T15:54:53Z http://eprints.uanl.mx/23831/ PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, Hagop M. Gómez Almaguer, David Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J. M. RC Medicina Interna, Psiquiatría, Neurología Wolters Kluwer Health 2022 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/23831/1/23831.pdf http://eprints.uanl.mx/23831/1.haspreviewThumbnailVersion/23831.pdf Jabbour, E. y Martinelli, G. y Vignetti, M. y Kantarjian, Hagop M. y Gómez Almaguer, David y Minami, Y. y Dombret, H. y Hennessy, M. y Vorog, A. y Wang, B. y Ribera, J. M. (2022) PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study. HemaSphere, 6. pp. 1643-1644. ISSN 2572-9241 http://doi.org/10.1097/01.HS9.0000849904.09812.c6 doi:10.1097/01.HS9.0000849904.09812.c6 |
| spellingShingle | RC Medicina Interna, Psiquiatría, Neurología Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, Hagop M. Gómez Almaguer, David Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J. M. PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| title_full | PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| title_fullStr | PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| title_full_unstemmed | PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| title_short | PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| title_sort | pb1762 ponatinib versus imatinib with reduced intensity chemotherapy in patients with newly diagnosed philadelphia chromosome positive ph acute lymphoblastic leukemia all phallcon study |
| topic | RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/23831/1/23831.pdf |
| work_keys_str_mv | AT jabboure pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT martinellig pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT vignettim pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT kantarjianhagopm pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT gomezalmaguerdavid pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT minamiy pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT dombreth pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT hennessym pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT voroga pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT wangb pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT riberajm pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy |